Dianthus Therapeutics, Inc.
DNTH
$85.74
-$0.41-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -173.66M | -162.34M | -126.35M | -114.75M | -100.73M |
| Total Depreciation and Amortization | 371.00K | 428.00K | 409.00K | 426.00K | 438.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.40M | 16.12M | 12.59M | 10.53M | 8.62M |
| Change in Net Operating Assets | 20.61M | 16.73M | 3.82M | 3.57M | 803.00K |
| Cash from Operations | -130.29M | -129.06M | -109.52M | -100.23M | -90.87M |
| Capital Expenditure | -199.00K | -213.00K | -106.00K | -126.00K | -97.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -271.40M | -122.62M | -183.04M | -241.11M | -266.41M |
| Cash from Investing | -271.60M | -122.83M | -183.15M | -241.24M | -266.51M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.02B | 280.49M | 315.09M | 40.70M | 40.18M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.71M | -364.00K | -172.00K | 0.00 | -2.24M |
| Cash from Financing | 1.02B | 280.13M | 314.92M | 40.70M | 37.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 617.49M | 28.23M | 22.25M | -300.77M | -319.44M |